Park­er In­sti­tute-al­lied Tes­sa grabs an $80M round for its next-gen can­cer cell ther­a­pies

Last sum­mer the Park­er In­sti­tute for Can­cer Im­munother­a­py raised eye­brows in R&D cir­cles with its an­nounce­ment that it was al­ly­ing it­self with a lit­tle-known biotech based on Sin­ga­pore that was tak­ing a nov­el ap­proach to adop­tive cell ther­a­pies. Now, the biotech — Tes­sa Ther­a­peu­tics — has raised $80 mil­lion from a well-heeled group that in­cludes the sov­er­eign wealth fund for Sin­ga­pore to fin­ish a Phase III quest aimed at one of the Holy Grails of can­cer R&D.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.